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Abstract
Background: Integrin-linked kinase (ILK) is a highly evolutionarily conserved, multi-domain signaling protein that localizes
to focal adhesions, myofilaments and centrosomes where it forms distinct multi-protein complexes to regulate cell
adhesion, cell contraction, actin cytoskeletal organization and mitotic spindle assembly. Numerous studies have
demonstrated that ILK can regulate the phosphorylation of various protein and peptide substrates in vitro, as well as
the phosphorylation of potential substrates and various signaling pathways in cultured cell systems. Nevertheless, the
ability of ILK to function as a protein kinase has been questioned because of its atypical kinase domain.
Methodology/Principal Findings: Here, we have expressed full-length recombinant ILK, purified it to .94% homogeneity,
and characterized its kinase activity. Recombinant ILK readily phosphorylates glycogen synthase kinase-3 (GSK-3) peptide
and the 20-kDa regulatory light chains of myosin (LC20). Phosphorylation kinetics are similar to those of other active kinases,
and mutation of the ATP-binding lysine (K220 within subdomain 2) causes marked reduction in enzymatic activity. We show
that ILK is a Mn-dependent kinase (the Km for MnATP is ,150-fold less than that for MgATP).
Conclusions/Significance: Taken together, our data demonstrate that ILK is a bona fide protein kinase with enzyme kinetic
properties similar to other active protein kinases.
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Introduction
Integrin-linked kinase (ILK) was discovered as an interactor of
integrin b1 and b3 cytoplasmic domains [1], which localizes to
focal adhesion plaques and to centrosomes [2,3], and is composed
of three distinct domains: an N-terminal ankyrin-repeat domain, a
pleckstrin homology (PH)-like domain and a kinase catalytic
domain [2]. The domains are highly evolutionarily conserved, and
genetic studies in model organisms such as C.elegans, Drosophila,
Xenopus laevis, zebrafish, and mice have demonstrated an essential
role of ILK in embryonic development and diverse physiological
functions, and have confirmed tight functional linkages of ILK
with integrins [2,4]. Inhibition of ILK kinase activity has
significant effects on cell survival and proliferation in cancer cells
relative to most normal cells [5], suggesting that, although ILK
kinase activity may be silenced in most normal cells, it becomes
activated in cancer cells where it is required for cell survival and
proliferation.
The kinase domain of ILK is atypical in that it lacks the highly
conserved Asp-Phe-Gly (DFG) and His-Arg-Asp (HRD) motifs,
but possesses the invariant Lys residue involved in ATP binding, as
well as the invariant Ala-Pro-Glu (APE) motif. This has resulted in
the classification of ILK as a pseudokinase [2,6]. Recent structure-
function analyses of other ‘‘pseudokinases’’, such as CASK and
haspin [7,8], both of which lack the DFG motif (haspin also lacks
the APE motif), have clearly demonstrated that these kinases are
catalytically functional. ErbB3, a member of the epidermal growth
factor receptor family and long thought to be inactive as a kinase,
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has now been shown to be catalytically active [9,10]. These studies
have identified unusual mechanisms of catalysis for these enzymes,
thereby challenging a simplistic categorization of kinases based on
amino acid sequence alone.
Kinase assays using either recombinant wild-type or mutant
ILKs, or ILK purified from tissues or immunoprecipitated from
mammalian cellular lysates have shown that ILK can regulate the
phosphorylation of several protein substrates, e.g., integrin b1
cytoplasmic domain [1], the ILK-binding protein, b-parvin [11],
Akt/PKB [5,12–25], GSK-3b [24,26–35], the 20-kDa regulatory
light chains of myosin, LC20 [36–40], the myosin targeting subunit
of myosin light chain phosphatase, MYPT1 [38,39], protein
phosphatase inhibitors, PHI-1, KEPI and CPI-17 [36,37,41,42],
and a-NAC [20]. Indeed, ILK was discovered completely
independently as a calcium-independent myosin light chain
protein kinase [40], as well as a kinase capable of directly
phosphorylating MYPT1 [38,39] and the CPI-17 family of protein
phosphatase inhibitors [42]. In addition, ILK-null mutants in
zebrafish are rescued by wild-type, kinase-active ILK, but not by
ILK containing mutations within the kinase domain [13], and
kinase-deficient mutants of ILK have been identified in the
myocardium of patients with dilated cardiomyopathy [43].
However, other studies have shown that kinase domain
mutations can support normal embryonic development and rescue
genetic defects in vivo [44,45], challenging the requirement of
kinase activity for ILK function. The C-terminal catalytic and the
N-terminal ankyrin domains of ILK interact directly with several
proteins, suggesting that ILK fulfils an adaptor/scaffolding
function in addition to a kinase function. These complex
protein-protein interactions [2,4,46] are also likely to regulate
the kinase activity of ILK, as indicated by the recent structure
determination of a complex between the ILK kinase domain and
the C-terminal calponin homology (CH2) domain of a-parvin [47].
Thus, controversy persists as to whether ILK can function as a
protein kinase [45], especially since the structure of the full-length,
uncomplexed protein has yet to be solved, and rigorous
characterization of the kinase activity of purified ILK is lacking.
To address these issues, we have expressed and purified full-
length wildtype and mutant ILKs in the baculovirus/insect cell
system and characterized their kinase activities. We show that ILK
is indeed a protein kinase capable of phosphorylating protein and
peptide substrates with comparable kinetics to those of other
protein kinases. We find that ILK has a strong preference for the
Mn2+ divalent cation. We also show that the ATP-coordinating
lysine residue, K220, is required for full activation of ILK in vitro.
ILK kinase activity is inhibited by interaction with its binding
partner, a-parvin. Together, these results argue that ILK is not a
pseudokinase, but an authentic protein kinase.
Results
Recombinant ILK phosphorylates GSK-3 crosstide and the
20 kDa regulatory light chain of myosin, LC20
A GST-ILK construct was cloned into baculovirus and GST-
ILK fusion protein was expressed in insect cells and purified as
described in Materials and Methods. As shown in Fig. 1A, separation
of the GST-ILK preparation by SDS-PAGE and staining of the
gel with Coomassie blue showed the presence of a full-length
protein with the expected MW of approximately 78 kDa and
purity of .94%. Western blot analyses with anti-ILK (Fig. 1B)
confirmed the identity of the band as GST-ILK. Although very
few other proteins were detected on the stained gel (Fig. 1A), we
analyzed the total protein complement of the ILK preparation by
mass spectrometry as described in Materials and Methods to ensure
that there were no other protein kinases present. As shown in
Table S1, although several insect proteins were minor contami-
nants of the preparation, no additional protein kinases were
detectable, ensuring that any protein kinase activity detected is due
to ILK. The presence of human ILK protein was also confirmed
by mass spectrometry with greater than 94% sequence coverage,
as shown in Fig. S1.
To analyze protein kinase activity, we utilized two well
characterized substrates of ILK, GST-GSK-3 a/b crosstide and
LC20. The GSK-3 crosstide is a commercially available peptide,
previously identified as a substrate of ILK [2,24,29]. The
phosphorylation of glycogen synthase kinase (GSK)-3b itself on
Ser-9 has been shown to be regulated by ILK in several cellular
systems [24,27,29,33]. Phosphorylation inactivates GSK-3b,
resulting in the stimulation of several downstream signaling
pathways that regulate cell proliferation and cell survival
[33,35,48]. LC20 has previously been shown to be directly
phosphorylated by ILK purified from smooth muscle tissue [40].
Experiments were performed using standard kinase reaction
conditions, including the use of Mg2+ and ATP, as outlined in
Materials and Methods. As shown in Fig. 1C, ILK readily
phosphorylates GSK-3 crosstide and LC20 in a manner dependent
on the concentration of ILK. The phosphorylation of LC20 and
GSK-3 crosstide by ILK also occurred in a time-dependent
fashion (Fig. 1D).
We next determined whether recombinant ILK phosphorylates
GSK-3 crosstide and LC20 at the previously identified serine
residues [27,29,31,33] by carrying out kinase assays with non-
radioactive ATP. Phosphorylation of the substrates was detected
by Western blot analysis using phospho-specific antibodies. As
shown in Fig. 1E, ILK phosphorylates GSK-3 crosstide at a serine
residue corresponding to serine 9 in GSK-3b and serine 21 in
GSK-3a. A large number of studies utilizing ILK dominant-
negative mutants, siRNA and small molecule inhibitors have
reported that ILK can regulate GSK-3 phosphorylation on Ser9/
21 [reviewed in 2]. Other studies have reported direct phosphor-
ylation of GSK-3 by recombinant GST-ILK [24,33]. LC20 was
also identified as a substrate of ILK, and shown to be
phosphorylated at Thr-18 and Ser-19 [40]. As shown in Fig. 1E,
recombinant ILK directly phosphorylates LC20 on serine 19.
These data demonstrate that ILK directly phosphorylates
physiologically relevant substrates in vitro.
ILK autophosphorylation
Most protein kinases are capable of autophosphorylation [7],
and autophosphorylation activity is frequently employed as a test
for kinase activity [49]. To determine whether ILK can undergo
autophosphorylation, we carried out kinase reactions in the
absence of exogenous substrates. As shown in Fig. 2A and 2B,
ILK is readily autophosphorylated in a concentration-dependent
manner.
Enzyme kinetics
The analysis of the kinase activity of another apparent
‘‘pseudokinase’’, CASK [7], demonstrated unusual divalent cation
requirements for catalytic activity. Indeed, CASK activity is
inhibited by divalent cations and is constitutively active in the
absence of cations. Coordination of the b and c phosphates of
ATP by Mg2+ ions catalyzes phosphotransfer reactions by most
protein kinases [50,51]. We therefore characterized the divalent
cation requirement of ILK kinase activity. Kinase activity was
readily detected in the presence of MgCl2 and MnCl2, but not in
the presence of CaCl2, ZnSO4 or EDTA (Fig. 2C), demonstrating
a requirement for Mg2+ and Mn2+ cations.
Functional ILK Kinase Activity
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We compared the differential effects of Mg2+ and Mn2+ ions on
the kinase activity of the recombinant ILK protein. As shown in
Fig. 2D, the reaction velocity was significantly higher in the
presence of MnCl2 than MgCl2. ILK activity for LC20 was
markedly enhanced by low concentrations of Mn2+, peaking at
approximately 4–5 mM MnCl2, and then declined gradually at
higher concentrations.
We used Michaelis-Menten kinetics to determine the Km, Vmax,
and Vmax:Km values for ATP and GSK-3 crosstide. As shown in
Fig. 3A and 3B, and Table 1, the Km for ATP is` 150-fold lower in
the presence of MnCl2 (2.0 mM) than MgCl2 (311 mM). Similarly,
the Vmax:Km ratio is significantly higher in MnCl2 than in MgCl2
(Table 1), demonstrating a two order of magnitude increase in
enzymatic efficiency in the presence of manganese. We also
determined the Km for GSK-3 crosstide in the presence of MgCl2
or MnCl2 (Figs. 3C and 3D). The calculated Km values (,3.2 mM)
are entirely within the range of Km values of other active protein
kinases [7], and compare well with the reported Km
ATP values of
Figure 1. Purified GST-ILK is an active serine kinase. (A) Coomassie blue-stained polyacrylamide gel showing a single protein band at
approximately 78 kDa, the predicted molecular weight of the GST-ILK fusion protein, prepared as described in Materials and Methods. (B) Western
blot analysis using antibodies specific for ILK confirm the identity of the 78 kDa band. (C) Analysis of the concentration dependence of the protein
kinase activity of GST-ILK using GSK-3 crosstide and LC20 as substrates. Experiments were carried out using standard kinase reaction conditions
(described in Materials and Methods) in the presence of 10 mM MgCl2. Representative autoradiographs (upper panels) show the amount of
32P-
phosphate incorporation with increasing concentrations of GST-ILK. Coomassie stains of SDS-gels (lower panels) depict equal loading of substrate
into the kinase reaction. (D) Time course of the protein kinase activity of GST-ILK. Reactions were performed as described in C using GSK3 crosstide
and LC20 as substrates. The amount of ILK was held constant at 30 ng. (E) Phosphorylation of Ser9 on GSK3 crosstide and Ser19 on LC20. Each
substrate was incubated with 150 ng of GST-ILK in 25 ml of kinase reaction buffer (see Materials and Methods) for the indicated times in the presence
of 500 mM cold ATP. Western blot analysis was carried out using phospho-specific antibodies as described in Materials and Methods. Ponceau S stains
of membranes are provided as loading controls.
doi:10.1371/journal.pone.0012356.g001
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CASK [7] and haspin [8], both of which were previously proposed
to be pseudokinases. The calculated Vmax and Vmax:Km values
(Table 1) are also comparable [7,8]. These data indicate that ATP
coordination is sensitive to divalent cations, being much more
efficient in MnCl2 compared to MgCl2. However, in saturation
conditions of ATP, the Km for substrate (GSK-3 crosstide) is similar
in the presence of either divalent cation. These data demonstrate
that ILK is an active protein kinase, whose overall kinetic properties
compare favorably with those of other active protein kinases.
a-Parvin inhibits ILK kinase activity
The recently reported crystal structure of the kinase domain of
ILK in complex with a-parvin shows that this complex, although
capable of binding ATP, is catalytically inactive, and that the
kinase domain of ILK can function as a scaffold for protein-
protein interactions [47]. However, these studies used suboptimal
assay conditions, in particular ILK was incubated with protein or
peptide substrates, Mg2+ and unlabeled ATP prior to starting the
reaction with radiolabeled ATP. In this case, the protein substrate
will be phosphorylated by cold ATP so that addition of
[c-32P]ATP will fail to incorporate [32P]phosphate. Also, no
quantification of the data was presented.
It is conceivable that the ‘‘inactive’’ conformation and the
reduced ILK activity detected by Fukuda et al [47] is due to a-
parvin exerting a constraint on the kinase domain and locking it
into an inactive conformation. We therefore investigated whether
the interaction of a-parvin with ILK in vitro can directly modulate
ILK kinase activity by purifying the ILK/a-parvin complex from
Figure 2. ILK autophosphorylation and divalent cation requirements for ILK activity. (A) Autoradiograph showing autophosphorylation of
GST-ILK. Reactions were carried out in the absence of exogenous substrate for 60 min using 80 ng of ILK in the presence of 5 mM MnCl2. (B)
Concentration-dependent increase in autophosphorylation of ILK. An autoradiograph is shown to demonstrate that the amount of
autophosphorylation increases with increasing amounts of ILK. Reactions were carried out as described in A using the indicated amounts of ILK.
(C) Autoradiograph demonstrating ILK kinase activity in the presence of a variety of divalent cations. Reactions were carried out for 30 min using
30 ng of ILK. LC20 was used as the substrate. A Western blot for ILK demonstrates the presence of equal amounts of enzyme in each reaction. (D) The
effects of Mg2+ and Mn2+ on the velocity of ILK activity. Top, autoradiographic images and Coomassie stains demonstrating increased kinase activity
of ILK in MnCl2. Reactions were carried out for 30 min using 30 ng of ILK and the indicated concentrations of each cation. LC20 was used as the
substrate. Bottom, quantification of the radiographic data. A plot of reaction velocity against increasing concentrations of the indicated cations is
shown.
doi:10.1371/journal.pone.0012356.g002
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cells co-expressing full-length ILK and a-parvin via the baculo-
virus system. As shown in Fig. 4A, ILK was co-expressed with a-
parvin and the two proteins were demonstrated to exist as a
complex as shown by co-immunoprecipitation (Fig. 4B). Interest-
ingly, the ILK/a-parvin complex is significantly less active
(Fig. 4C) than ILK alone, while the ILK-c-parvin complex
exhibited a level of activity approaching that of wildtype ILK,
suggesting that distinct parvins could modulate ILK kinase activity
under physiological and pathological conditions in vivo [2,4].
The ATP-binding Lysine 220 is required for ILK kinase
activity
Although ILK lacks the Mg2+-ATP coordinating motif, DFG, as
well as the HRD motif within the activation loop involved in
phosphotransfer, ILK possesses the invariant ATP-coordinating
lysine residue within subdomain 2 [1], K220, as well as the
invariant APE motif. Mutation of K220 to alanine or methionine
has shown that K220 is essential for ILK function in vitro and in
vivo. Specifically, K220 of ILK has been shown to be essential for
kidney development and function [45], in enhancing adhesion and
focal adhesions during bacterial colonization of epithelial cells
[52], and in cardiac function [13,43]. Although the effect of the
‘‘knock-in’’ K220M mutation of ILK on renal development and
function was attributed to an adaptor role of ILK in impaired
parvin interaction [45], it is equally likely that it is due to impaired
kinase activity. Indeed, the crystal structure of the ILK kinase
domain in complex with a-parvin indicates that the K220 ATP-
binding motif is well separated from the a-parvin-contacting
residues, M402 and K403 in the G helix, and parvin does not have
a direct effect on ATP binding [47], making it unlikely that the
major developmental effect of mutating K220 is solely through a-
parvin binding.
Therefore, we investigated whether Lys-220 is indeed required
for ILK catalytic function by analyzing recombinant protein in
which this residue is mutated to a non-coordinating alanine. We
prepared K220A ILK (see Experimental procedures) and compared its
kinase activity with that of wild-type ILK under the optimal
conditions established in this study. As shown in Fig. 5A and 5B,
wild-type and K220A ILK, identified with anti-ILK, are expressed
at comparable levels (Fig. 5B). The K220A mutation was
confirmed by DNA sequencing (see Materials and Methods). As
shown in Fig. 5C, the kinase activity of the K220A ILK mutant in
the presence of Mn2+ is significantly reduced over a range of ATP
concentrations relative to that of wild-type ILK, demonstrating
that K220 is indeed required for maximal catalytic activity of ILK.
Similar results were obtained when the reactions were carried out
in the presence of Mg2+ (Fig. 5D).
Small molecule inhibitors of ILK kinase activity have been
developed and characterized in vitro and in vivo [5,53,54]. Because
Figure 3. Michaelis-Menten (MM) kinetics of GST-ILK. (A) MM plot of reaction velocity against increasing concentrations of ATP in the presence
of 10 mM MgCl2. Reactions were carried out for 30 min using 30 ng of ILK and 1 mg of GSK-3 crosstide as the substrate. (B) MM plot of reaction
velocity against increasing concentrations of ATP in the presence of 5 mM MnCl2. Reactions were carried out as described in A. (C) MM plot of
reaction velocity against increasing concentrations of GSK-3 crosstide in the presence of 10 mM MgCl2. Reactions were carried out for 30 min using
30 ng of ILK. The ATP concentration was 500 mM. (D) MM plot of reaction velocity against increasing concentrations of GSK3 crosstide in the presence
of 5 mM MnCl2. Reactions were carried out for 30 min using 30 ng of ILK. The ATP concentration was 500 mM. For all data points, values are reported
as means 6 SEM, n = 3. Km and Vmax values were calculated as described in Materials and Methods.
doi:10.1371/journal.pone.0012356.g003
Table 1. Michaelis-Menten enzyme kinetics for GST-ILK.
Km (mM) Vmax (nmol/mmol/min) Vmax:Km (610
25)
Mg2+/ATP 311.3 27.9 8.9
Mn2+/ATP 2.0 29.0 1450
GSK3 (Mg2+) 3.2 142.9 4465
GSK3 (Mn2+) 3.2 117.0 3656
Substrate and enzyme velocity data were fit to a Michaelis-Menten model and
Vmax and Km were calculated using the Michaelis-Menten model features in
GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, CA). To
calculate the ratio of Vmax:Km, the values for Vmax were transformed from nmol/
mmol/min to mmol/mmol/min.
doi:10.1371/journal.pone.0012356.t001
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of the robust catalytic activity of ILK characterized here, we
wanted to confirm the inhibitory activity of QLT-0267 [5] under
optimal kinase reaction conditions. As shown in Fig. 5E, QLT-
0267 inhibits ILK activity in an ATP-competitive manner. In
addition, QLT-0267 was found to be the most potent inhibitor of
ILK activity as compared to several other kinase inhibitors (Fig.
S2).
Discussion
The data presented in this paper establish that ILK is an active
serine/threonine protein kinase despite having an atypical kinase
domain. We have conducted a detailed kinetic analysis of the
kinase activity of wildtype ILK and of the K220A mutation that is
unable to co-ordinate ATP, and determined that ILK is
significantly more active in the presence of Mn2+ than Mg2+ ions.
These findings have implications for the regulation of ILK kinase
activity in vivo.
Recent structure-function analyses of other ‘‘pseudokinases’’,
such as CASK [7] and haspin [8], which have atypical kinase
domains similar to ILK, have clearly demonstrated that atypical
kinase domains can be functional and are capable of catalysis. Novel
mechanisms for kinase activity have been identified through these
structure-function analyses [8,55]. The structure of the ILK kinase
domain has recently been solved, albeit as a complex with a-parvin,
resulting in an inactive conformation and demonstrating that this
domain of ILK can form a bi-lobed kinase-like conformation and
can bind ATP, but can also function as a protein scaffold.
Here, we have established that purified recombinant full-length
ILK is catalytically active, capable of phosphorylating several
substrates such as GSK-3 and LC20, both of which have previously
been demonstrated to be physiological substrates of ILK (reviewed
in 2). We have also established that the Km values for ATP and
peptide or protein substrates of ILK are within the range of other
protein kinases [7,8], and that the Km values of ILK for MnATP
are much lower, and the Vmax:Km much higher than for MgATP,
and comparable to those of CASK and haspin [7,8]. The
differential effects of manganese and magnesium on ILK kinase
activity are interesting and are very similar to those described
recently for the kinase activity of leucine-rich repeat kinase 2
(LRRK2) [56]. Together, these results suggest that ILK is a more
efficient kinase in the presence of manganese.
We have also established the important role of Lys-220 for the
enzymatic activity of ILK. This invariant lysine residue in
subdomain 2 coordinates ATP, and mutation to alanine results
in significant inhibition of catalytic activity. It is surprising that the
mutation of K220 did not completely abrogate activity, but instead
resulted in a substantially less active kinase. The reasons for this
are unclear at present, although a similar reduction in activity was
noted when the analogous lysine residue was mutated in haspin
[8]. Our finding that mutation of K220 results in a significantly
less active kinase is important with regard to the interpretation of a
recent genetic study in which knock-in of the K220M mutant
resulted in a dramatic kidney development defect [45] likely due,
at least in part, to defects in renal branching morphogenesis [57].
The interpretation of the authors was that this mutant fails to bind
a-parvin, resulting in defective function, and it was suggested that
K220 represents a binding site for a-parvin. However, as we have
shown that this mutation also results in a significant reduction in
ILK activity, it is entirely possible that the defects in the kidney are
Figure 4. Binding of a-parvin inhibits ILK kinase activity. (A) Western blot showing co-expression of GST-ILK and His-a-parvin using antibodies
to ILK and a-parvin. (B) Co-immunoprecipitation of ILK and a-parvin. The complex of ILK and a-parvin was immunoprecipitated using ILK and blotted
using antibodies to a-parvin. Non-immune IgG served as a control. (C) Autoradiograph showing kinase activity of ILK alone, ILK complexed with a-
parvin (ILK/a-parvin) or ILK complexed with c-parvin (ILK/c-parvin). Reactions were carried out for 30 min using 30 ng of each enzyme preparation
and GSK-3 crosstide as the substrate. Western blot analysis for ILK and Coomassie stains of SDS-gels are provided as loading controls for equal
amounts of ILK and GSK-3 crosstide substrate, respectively.
doi:10.1371/journal.pone.0012356.g004
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due to a requirement for kinase activity, especially since ILK
activity and GSK-3 phosphorylation have been shown to be
required for branching morphogenesis of kidney tubular epithelial
cells [57].
Also, it is unclear how K220 would be involved in a-parvin
binding since the ILK kinase domain-parvin structure shows that
the parvin-contacting residues, M402 and K403 in the G helix, are
very distant from the K220 ATP-coordinating amino acid in the
nucleotide-binding cleft [47]. This result is consistent with our data
showing loss of catalytic activity of the K220A mutant towards
exogenous substrates. We have also demonstrated here that a-
parvin binding to ILK results in significant inhibition of kinase
activity, consistent with the inactive conformation of the parvin-
bound kinase domain described by Fukuda et al [47].
Fukuda et al [47] concluded that ILK does not exhibit kinase
activity based on the inactive conformation of the ILK kinase
domain in complex with the CH2 domain of a-parvin, and their
inability to detect phosphorylation of putative substrates (myelin
basic protein, integrin b1 and b3 C-termini fused to maltose-
binding protein, His-tagged a-parvin CH2 domain, and GST-Akt)
by bacterially-expressed, full-length ILK in complex with the
LIM1-2 domain of PINCH. Our results, on the other hand, clearly
Figure 5. ILK activity is reduced by mutation of K220 and by a specific pharmacological inhibitor, QLT0267, and is required for Ser9
phosphorylation of GSK-3b in vivo. (A) Coomassie-stained SDS-gel showing equal amounts of wild-type GST-ILK (ILKWT) and mutant GST-ILK
(ILKK220A) prepared as described in Materials and Methods. (B) Western blot analysis using antibodies specific for ILK to confirm the identities of ILKWT
and ILKK220A. Western blot analysis confirmed the presence of equal amounts of protein for both constructs. (C) Top, plot of reaction velocity with
increasing ATP concentrations for ILKWT and ILKK220A in 5 mM MnCl2. Bottom, autoradiographic images demonstrating ILK kinase activity for ILK
WT
and ILKK220A with increasing ATP concentrations. Reactions were carried out for 30 min using 30 ng ILK and GSK3 crosstide as the substrate. (D) Plot
of reaction velocity with increasing ATP concentrations for ILKWT and ILKK220A in 10 mM MgCl2. Reaction conditions were as described in C. (E) Kinase
activity of GST-ILK in the presence of 100 nM QLT0267, a specific small molecule inhibitor of ILK. Reactions were carried out for 30 min using 30 ng
ILK with GSK3 as the substrate.
doi:10.1371/journal.pone.0012356.g005
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demonstrate that the conclusion that ILK is a pseudokinase [6,58]
is not valid. Here, we have provided unequivocal data that
demonstrate that purified recombinant ILK is active as a serine/
threonine protein kinase in vitro.
The regulation of the kinase activity of ILK in vivo is likely to be
dynamic and complex, depending on multiple factors such as
protein-protein interactions and subcellular localization, and the
availability of divalent cations, in particular Mn2+, as well as
phosphoinositides. Although the cellular concentrations of man-
ganese are much lower than magnesium, the concentrations of
divalent cations may vary significantly in different subcellular
niches, likely making ILK more or less active in different protein
complexes. Furthermore, our results, when put into context with
other reports, clearly point to tissue-specificity of the kinase versus
adapter roles of ILK in vivo, and these functions are likely not
mutually exclusive. For example, the binding of a-parvin to the
ILK catalytic domain results in the inhibition of the kinase activity,
suggesting that dynamic protein-protein interactions within cells
can regulate ILK kinase activity. Tissue-specific knock out of ILK,
as well as tissue specific modulation of ILK using kinase-deficient
dominant-negative constructs, have clearly shown a requirement
of kinase function in vivo, for example for neuronal polarity and
dendrite and axon growth [26,29,59] and cardiac function
[13,43].
Future studies aimed at solving the crystal structure of full-
length, uncomplexed ILK, as well as various ILK complexes will
be necessary to understand the catalytic mechanism and complex
regulation of this atypical protein kinase. To paraphrase a recent
review on ILK activity [58], the pseudokinase is dead, long live the
kinase!
Materials and Methods
Cloning and purification of GST-ILK, GST-ILKK220A, and
His-a-parvin constructs
DNA primers for human ILK (NM_004517) and a-parvin
(NM_018222) were synthesized, the cDNAs cloned by PCR and
the sequences of the products verified by DNA sequencing. The
sequences of the primers and GST fusion proteins are provided in
Methods S1. The verified ILK gene product was sub-cloned into the
pAcG2T plasmid (BD PharMingen) for expression in insect cells.
The cloned a-parvin gene product was similarly sub-cloned into
the pAcSPHis plasmid (BD PharMingen). The human ILKK220A
cDNA was generated by site-directed mutagenesis as described
previously [23], and was sub-cloned into baculovirus expression
plasmid pAcSPG4T (BD PharMingen). Highly purified plasmid
DNAs containing ILK, ILKK220A, or a-parvin were then prepared
using a miniprep DNA purification kit (QIAGEN).
Transfection and amplification of recombinant
baculovirus in Sf9 cells
Purified pAcG2T-ILK, pAcSPG4T-ILKK220A, and pAcSPHis-a-
parvin plasmids were transfected separately with linear AcNPV
DNA (BD PharMingen) into Spodoptera frugiperda (Sf9) cells
(Invitrogen) to produce recombinant baculoviruses (Methods S1).
In brief, Sf9 cells were seeded into 6-well plates, transfected with
0.8–2.0 mg of each construct using 4 ml CellFECTIN reagent
(Gibco BRL) and 0.2 mg BaculoGoldTM DNA (BD PharMingen)
in serum-free media at 27uC for 4 h. TNM-FH + 10% FBS was
then added and the cells were cultured at 27uC for 4–5 days to
propagate baculovirus. Virus-containing medium was then
harvested, centrifuged to remove cellular debris and stored at
280uC.
Following initial transfection, homologous recombinant bacu-
loviruses for the various gene products were sequentially amplified
to a high viral titer in Sf9 cells for subsequent large-scale protein
expression. (Methods S1). In brief, for initial amplification, Sf9 cells
were seeded into T75 flasks, recombinant baculovirus prepared as
outlined above was added and the cells were propagated at 27uC
for 4 days. The medium was harvested, centrifuged at 2,0006g to
remove cellular debris and collected. The amplification step was
then repeated.
Further amplification was achieved using suspension-cultured
Sf9 cells. Cells were seeded into a spinner flask (BellCo),
recombinant baculovirus was added to the flask and the cells
were cultured at 27uC in a Cellgro Stirrer (Thermolyne) for 4 days.
The cell debris was then removed by centrifugation and the
supernatant containing baculovirus was stored at 4uC for up to 6
months.
Expression of recombinant proteins in insect cells
The recombinant ILK-, ILKK220A-, or a-parvin-encoding baculo-
viruses were infected into Sf9 insect cells. For production of the
ILK/a-parvin complex, insect cells were co-transfected with equal
amounts of ILK and a-parvin baculovirus. The recombinant
proteins were expressed under the control of the PH promoter.
Proteins were expressed in 56108 Sf9 cells (Invitrogen) in 500 ml
of TNM-FH medium +10% FBS using an MOI of 5. Cells were
grown in a spinner-flask with continuous stirring at 80 rpm and
27uC for 3 days. Cells were harvested by centrifugation at 1,0006g
at 4uC for 5 min. The supernatant was carefully decanted and the
cell pellets were processed immediately for affinity column
purification.
Purification of expressed proteins
Purification of the expressed ILK proteins (WT and K220A
mutants) or the ILK/a-parvin complex was performed by affinity
column chromatography. Recombinant proteins were isolated from
Sf9 cells by mild sonication (3630 s cycles) in 86 volume of Lysis
Buffer (20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM EDTA,
1% Triton-X-100, 1% NP40, 16 Protease Inhibitor Cocktail
solution, 0.1 mM PMSF) and the lysate was cleared of cellular
debris by centrifugation at 12,000 rpm for 10 min at 4uC. The
cleared lysate was then applied to a glutathione-agarose column
(Sigma-Aldrich). For large-scale purification, proteins were batch-
bound to the beads by rotation at 4uC for 20 min. The beads were
then collected by centrifugation at 1,0006g at 4uC for 3 min. The
supernatant was carefully removed, the beads were resuspended in
15 ml of ice-cold High Salt Wash Buffer (50 mMTris-HCl, pH 7.5,
500 mM NaCl, 1 mM EDTA, 0.1 mM PMSF) and loaded onto a
column. All washes and elutions were performed at 4uC. The
column was washed with 5 column volumes of High Salt Wash
Buffer, followed by 5 column volumes of Low Salt Wash Buffer
(50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.1 mM
PMSF). The bound GST-ILK was released from the column by
elution with Glutathione Elution Buffer (50 mM Tris-HCl, pH 7.5,
50 mM NaCl, 1 mM EDTA, 10 mM glutathione, 0.05 mM
PMSF). Fractions (0.5 ml) were collected, pooled and stored at
280uC. Purification of GST-ILK, GST-ILKK220A and GST-ILK/
His-a-parvin yielded approximately 50–60 mg of purified protein
from 1 L of Sf9 insect cells. Stock solutions of GST-ILK, GST-
ILKK220A and GST-ILK/His-a-parvin, each at a concentration of
20 ng/ml, were prepared and stored at 280uC.
Proteomics
Thirty micrograms of recombinant GST-ILK, including some
GST alone, was resolved by 10% SDS-PAGE and stained with
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blue-silver Coomassie [60]. The stained lane was cut into three
sections: between the GST band and the ILK band, the ILK band
itself and above the ILK band. The region of the gel including the
GST band and below was not analyzed since there are no known
kinases smaller than GST (27 kDa). Proteins in the three gel slices
were reduced, alkylated, digested with trypsin and analyzed by
liquid chromatography-tandem mass spectrometry exactly as
described [61]. The fragment spectra were searched against the
SwissProt human protein database to confirm the presence of ILK.
They were then searched against a library compiled from all
Order Lepidoptera sequences in GenBank (37,435 sequences) using
Mascot (v2.2). All identified Lepidoptera proteins meeting criteria for
a 1% false discovery rate can be found in Table S1.
Kinase activity assay
Kinase activity assays were performed using the following
standard conditions: 30 ng of GST-ILK purified from Sf9 insect
cells, 2 mg of the substrate GST-GSK3 crosstide (Cell Signaling
Technology) and c32P-labeled ATP (hot ATP:cold ATP =1:1000;
PerkinElmer) were added to the Kinase Reaction Buffer (25 mM
Tris-HCl, pH 7.5, 5 mM b-glycerophosphate, 0.1 mM Na3VO4,
10 mM MgCl2) in a final volume of 20 ml. Reactions were carried
out with constant shaking (120 rpm) for 30 min at 30uC in a
TempMaster benchtop incubator/shaker (Fisher Scientific). Full-
length LC20 (1.5 mg) was used as a substrate in certain
experiments. In some experiments, various cations (MnCl2, CaCl2,
ZnSO4) were substituted for MgCl2 in the reaction buffer. Their
use and specific concentrations are indicated in the appropriate
figures. Phosphorylated proteins were electrophoresed on 10–20%
Tricine gradient gels (Invitrogen) using NuPAGE MES SDS
running buffer (Invitrogen). Proteins were stained with Coomassie
Blue and incorporation of radioactive phosphate was visualized
using autoradiography. For quantification, electrophoresis was
carried out in triplicate, individual bands were excised and samples
were analyzed in a liquid scintillation counter. For experiments
involving kinase inhibitors, stock inhibitors in DMSO were added
directly to the kinase reaction at a concentration of 1 mM.
Inhibitors included Dasatinib (Brystol-Myers Squibb), GF109203x
(Sigma-Aldrich), MLCK inhibitor, CDK 1/5 inhibitor (Calbio-
chem), AMPK inhibitor compound C (Calbiochem) and QLT-
2067 (QLT Inc).
Western blot analysis
Western blotting was carried out as previously described
[23,24]. Primary antibodies used were rabbit-anti-a-parvin
(Sigma), mouse-anti-ILK (BD Biosciences), rabbit-anti-phospho-
Ser19-LC20 (Rockland Immunochemicals, Gilberville, PA) and
rabbit-anti-phospho-Ser9-GSK3b (Cell Signaling Technology). All
primary antibodies were used at a dilution of 1:1000. Proteins
were visualized by chemiluminescence using Supersignal (Pierce)
or by fluorescence using the Odyssey system (Li-Cor Biosciences,
Lincoln, NA). Adobe Photoshop was used for image adjustments.
All image processing was applied to the whole image and levels
were adjusted in a linear fashion.
Michaelis-Menten kinetics
Substrate and enzyme velocity data were fit to a Michaelis-
Menten model and Vmax and Km were calculated using the
Michaelis-Menten model features in GraphPad Prism 5.00 for
Windows (GraphPad Software, San Diego, CA). Substrate
concentrations were varied and enzyme velocity (nmol sub-
strate/mmol enzyme/min) was calculated from the original counts
per minute (CPM) values and the specific activity of the
radiolabeled ATP derived from liquid scintillation counting.
Supporting Information
Methods S1
Found at: doi:10.1371/journal.pone.0012356.s001 (0.04 MB
DOC)
Figure S1 Mass spectrometry analysis of ILK. Fragment spectra
were analyzed by liquid chromatography-tandem mass spectros-
copy and searched against the SwissProt human protein data base
to confirm the presence of ILK. Matching peptides are indicated
in red. Sequence coverage exceeded 94%.
Found at: doi:10.1371/journal.pone.0012356.s002 (3.68 MB TIF)
Figure S2 Effect of various kinase inhibitors on ILK kinase
activity. Autoradiograph demonstrating ILK kinase activity in the
presence of a variety kinase inhibitors. Reactions were carried out
for 30 min using 30 ng of ILK and 10 mM MgCl2. LC20 was
used as the substrate. Densitometric quantification of the bands is
provided below the autoradiograph.
Found at: doi:10.1371/journal.pone.0012356.s003 (3.46 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0012356.s004 (0.03 MB
XLS)
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